DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vincristine (Vincristine) - Disability - Suspected Cause - Side Effect Reports

 
 



Index of reports > Disability (46)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine disability. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 46   Next >>

Possible Vincristine side effects in 43 year old female

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-08-27

Patient: 43 year old female

Reactions: Off Label Use, Blindness

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Ifosfamide

Etoposide

Doxorubicin Hydrochloride

Vincristine



Possible Vincristine side effects in female

Reported by a physician from Canada on 2012-08-13

Patient: female

Reactions: Oral Herpes

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prednisolone
    Dosage: dose of last drug taken:100mg, date of recent dose taken prior to onset of ae:17/jun/2012
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Vincristine
    Dosage: route:intravenous push, dose of last drug taken:2mg, date of last dose taken prior to onset of ae:13
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Doxorubicin Hydrochloride
    Dosage: dose of last drug taken:91mg, date of last dose taken prior to onset of ae:13/jun/2012
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Mabthera
    Dosage: volume of last drug taken:343.5ml, dose concentration of last drug taken:1.99mg/ml, date of last do
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Cyclophosphamide
    Dosage: dose of last drug taken:1370mg, date of last dose taken prior to onset of ae:13/jun/2012
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Other drugs received by patient: Colace; Polyethylene Glycol; Tramadol Hydrochloride and Acetaminophen; Senokot; Valacyclovir Hydrochloride; Codeine; Benzydamine; Naproxen; Morphine; Preparation H Cream; Lidocaine; Valacyclovir Hydrochloride; Ranitidine; YAZ; Morphine; Pantoprazole; Acetaminophen; Diphenhydramine Hydrochloride; Suppository (Unk Ingredients)



Possible Vincristine side effects in female

Reported by a physician from United Kingdom on 2012-07-27

Patient: female

Reactions: Abasia, Myelopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Mabthera
    Dosage: unk
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Doxorubicin HCL
    Dosage: unk

Prednisone TAB
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Cyclophosphamide
    Dosage: unk



Possible Vincristine side effects in female

Reported by a physician from United Kingdom on 2012-07-27

Patient: female

Reactions: Myelopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Mabthera
    Indication: Burkitt's Lymphoma

Doxorubicin Hydrochloride
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Burkitt's Lymphoma

Prednisone
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Indication: Burkitt's Lymphoma



Possible Vincristine side effects in female

Reported by a physician from United Kingdom on 2012-07-23

Patient: female

Reactions: Abasia, Myelopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prednisone

Doxorubicin Hydrochloride

Vincristine

Mabthera
    Indication: Burkitt's Lymphoma

Cyclophosphamide



Possible Vincristine side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-07-17

Patient: female

Reactions: Palmar-Plantar Erythrodysaesthesia Syndrome, Paraesthesia

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Start date: 2012-05-24

Cyclophosphamide
    Start date: 2012-05-10

Vincristine
    Start date: 2012-05-10

Cyclophosphamide
    Start date: 2012-05-24
    End date: 2012-05-24

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-05-10

Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-05-24

Doxorubicin HCL
    Start date: 2012-05-10

Vincristine
    Start date: 2012-05-24
    End date: 2012-05-24

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-05-24

Other drugs received by patient: Rituximab; Prednisone; Prednisone; Prednisone; Rituximab; Rituximab



Possible Vincristine side effects in female

Reported by a physician from United Kingdom on 2012-07-16

Patient: female

Reactions: Abasia, Myelopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Indication: Product Used FOR Unknown Indication

Vincristine
    Indication: Product Used FOR Unknown Indication

Mabthera
    Indication: Burkitt's Lymphoma

Prednisone
    Indication: Product Used FOR Unknown Indication

Cyclophosphamide
    Indication: Product Used FOR Unknown Indication



Possible Vincristine side effects in 67 year old female

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-07-05

Patient: 67 year old female

Reactions: Cataract, Neuropathy Peripheral, Neutropenia

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Methotrexate
    Dosage: 3500 mg/m2
    Indication: Lymphoma

Rituximab (Rituximab) (Rituximab)
    Dosage: 375 mg/m2
    Indication: Lymphoma

Vincristine
    Dosage: 1.4 mg/m2
    Indication: Lymphoma

Procarbazine Hydrochloride
    Dosage: 100 mg/m2, 1 in 1 d
    Indication: Lymphoma



Possible Vincristine side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-07-03

Patient: female

Reactions: Palmar-Plantar Erythrodysaesthesia Syndrome

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Start date: 2012-05-10

Cyclophosphamide
    Start date: 2012-05-24

Doxorubicin HCL
    Start date: 2012-05-24

Vincristine
    Start date: 2012-05-10

Vincristine
    Start date: 2012-05-24

Rituxan
    Start date: 2012-05-24

Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Doxorubicin HCL
    Start date: 2012-05-10

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Rituxan
    Start date: 2012-05-10

Prednisone
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Rituxan
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Prednisone
    Start date: 2012-05-10

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Prednisone
    Start date: 2012-05-24



Possible Vincristine side effects in 62 year old female

Reported by a health professional (non-physician/pharmacist) from Switzerland on 2012-06-30

Patient: 62 year old female

Reactions: Off Label Use, JC Virus Infection, Progressive Multifocal Leukoencephalopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prednisone TAB
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Etoposide
    Indication: Hodgkin's Disease Recurrent

Procarbazine Hydrochloride
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Doxorubicin HCL
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Vincristine
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Cyclophosphamide
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Bleomycin Sulfate
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent



Possible Vincristine side effects in 21 year old male

Reported by a health professional (non-physician/pharmacist) from France on 2012-05-30

Patient: 21 year old male, weighing 82.6 kg (181.7 pounds)

Reactions: Toxic Optic Neuropathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Dexamethasone
    Dosage: unk
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-10-20
    End date: 2011-11-27

Valacyclovir Hydrochloride
    Dosage: 1 g, 1x/day
    Administration route: Oral
    Start date: 2011-10-13
    End date: 2011-12-07

Cerubidine
    Dosage: 60 mg, cyclic
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-10-20
    End date: 2011-11-10

Vfend
    Dosage: unk
    Start date: 2011-10-17
    End date: 2011-12-07

Phenoxymethyl Penicillin
    Dosage: 3 millioniu, 1x/day
    Administration route: Oral
    Start date: 2011-11-18
    End date: 2011-12-07

Vincristine
    Dosage: 2 mg, cyclic
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-10-20
    End date: 2011-11-10

Nexium
    Dosage: unk
    Administration route: Oral
    Start date: 2011-10-17
    End date: 2011-11-11

Nexium
    Dosage: unk
    Administration route: Oral
    Start date: 2011-11-15
    End date: 2011-12-07

Kidrolase
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-10-24
    End date: 2011-11-16

Other drugs received by patient: Methotrexate; Cyclophosphamide; Cytarabine



Possible Vincristine side effects in 35 year old male

Reported by a physician from Israel on 2012-05-29

Patient: 35 year old male

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: 25 mg/m2, m2for 2 cycles of standard beacopp
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2, for 2 cycles of standard beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2for 2 cycles of standard beacopp
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 600 mg/m2, for 4 cycles of escalated beacopp

Vincristine
    Dosage: 1.4 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Procarbazine
    Dosage: 700 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 1250 mg/m2 for 4 cycles of escalated beacopp

Bleomycin
    Dosage: 10 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Prednisone TAB
    Dosage: 280 mg/m2,for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 35 mg/m2, for 4 cycles of escalated beacopp



Possible Vincristine side effects in 46 year old female

Reported by a physician from Israel on 2012-05-29

Patient: 46 year old female

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Etoposide
    Dosage: 300 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Prednisone TAB
    Dosage: 280 mg/m2, for 6 cycles

Bleomycin Sulfate
    Dosage: 10 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Procarbazine
    Dosage: 700 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 45 year old female

Reported by a physician from Israel on 2012-05-25

Patient: 45 year old female

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: 25 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Bleomycin
    Dosage: 10 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 700 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Prednisone TAB
    Dosage: 280 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease



Possible Vincristine side effects in female

Reported by a physician from France on 2012-05-25

Patient: female, weighing 45.0 kg (99.0 pounds)

Reactions: Malnutrition, Febrile Neutropenia, Febrile Bone Marrow Aplasia

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Dactinomycin
    Dosage: last dose prior to sae : 29/mar/2012
    Indication: Neoplasm Malignant
    Start date: 2012-01-19

Vincristine
    Dosage: last dose prior to sae 28/mar/2012
    Indication: Neoplasm Malignant
    Start date: 2012-01-19

Doxorubicin HCL
    Dosage: last dose prior to sae 29/mar/2012
    Indication: Neoplasm Malignant
    Start date: 2012-01-19

Avastin
    Dosage: last dose prior to sae: 22/mar/2012
    Indication: Neoplasm Malignant
    Start date: 2012-01-19

Ifosfamide
    Dosage: last dose prior to sae 29/mar/2012
    Indication: Neoplasm Malignant
    Start date: 2012-01-19



Possible Vincristine side effects in male

Reported by a physician from France on 2012-05-25

Patient: male

Reactions: Toxic Optic Neuropathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Vincristine
    Dosage: 2mg cyclic
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2011-10-20
    End date: 2011-11-10

Phenoxymethyl Penicillin
    Dosage: 3iu6 per day
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-11-18
    End date: 2011-12-07

Nexium
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-10-17
    End date: 2011-12-07

Vfend
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-10-17
    End date: 2011-12-07

Dexamethasone
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-10-20
    End date: 2011-10-27

Valacyclovir Hydrochloride
    Dosage: 1g per day
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-10-13
    End date: 2011-12-07

Kidrolase
    Dosage: 10iu3 cyclic
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2011-10-24
    End date: 2011-11-16

Cerubidine
    Dosage: 60mg cyclic
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2011-10-20
    End date: 2011-11-10

Other drugs received by patient: Methotrexate; Cyclophosphamide; Cytarabine



Possible Vincristine side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-05-24

Patient: female

Reactions: Paraesthesia

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Start date: 2010-05-20
    End date: 2010-08-12

Vincristine
    Start date: 2010-09-02
    End date: 2010-10-14

Cyclophosphamide
    Start date: 2010-05-20
    End date: 2010-08-12

Cyclophosphamide
    Start date: 2010-09-02
    End date: 2010-10-14

Doxorubicin HCL
    Start date: 2010-09-02
    End date: 2010-10-14

Vincristine
    Start date: 2010-05-20
    End date: 2010-08-12

Other drugs received by patient: Prednisone TAB; Prednisone TAB



Possible Vincristine side effects in 21 year old male

Reported by a health professional (non-physician/pharmacist) from France on 2012-05-24

Patient: 21 year old male, weighing 82.6 kg (181.7 pounds)

Reactions: Toxic Optic Neuropathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Vfend
    Dosage: unk
    Start date: 2011-10-17
    End date: 2011-12-07

Nexium
    Dosage: unk
    Administration route: Oral
    Start date: 2011-11-15
    End date: 2011-12-07

Valacyclovir Hydrochloride
    Dosage: 1 g, 1x/day
    Administration route: Oral
    Start date: 2011-10-13
    End date: 2011-12-07

Dexamethasone
    Dosage: unk
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-10-20
    End date: 2011-11-27

Cerubidine
    Dosage: 60 mg, cyclic
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-10-20
    End date: 2011-11-10

Phenoxymethyl Penicillin
    Dosage: 3 millioniu, 1x/day
    Administration route: Oral
    Start date: 2011-11-18
    End date: 2011-12-07

Vincristine
    Dosage: 2 mg, cyclic
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-10-20
    End date: 2011-11-10

Nexium
    Dosage: unk
    Administration route: Oral
    Start date: 2011-10-17
    End date: 2011-11-11

Kidrolase
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-10-24
    End date: 2011-11-16

Other drugs received by patient: Cyclophosphamide; Cytarabine; Methotrexate



Possible Vincristine side effects in 27 year old male

Reported by a physician from Israel on 2012-05-23

Patient: 27 year old male

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Etoposide
    Dosage: 600 mg/m2,for 2 cycles of escalated beacopp

Vincristine
    Dosage: 1.4 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 1250 mg/m2, for 2 cycles of escalated beacopp

Prednisone TAB
    Dosage: 280 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2, for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease

Bleomycin Sulfate
    Dosage: 10 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2,for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2, for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 35 mg/m2, for 2 cycles of escalated beacopp

Procarbazine Hydrochloride
    Dosage: 700 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 46 year old female

Reported by a health professional (non-physician/pharmacist) from Israel on 2012-05-23

Patient: 46 year old female

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: 10 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 700 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Prednisone
    Dosage: 280 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Cytoxan
    Dosage: 650 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 46 year old female

Reported by a health professional (non-physician/pharmacist) from Israel on 2012-05-23

Patient: 46 year old female

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: 10 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Cytoxan
    Dosage: 650 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 700 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Prednisone
    Dosage: 280 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease



Possible Vincristine side effects in male

Reported by a physician from France on 2012-05-23

Patient: male

Reactions: Toxic Optic Neuropathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Vincristine
    Dosage: 2 mg per course
    Start date: 2011-10-27

Cerubidine
    Dosage: 60 mg per course
    Start date: 2011-10-20

Kidrolase
    Start date: 2011-10-24

Vfend
    Start date: 2011-10-17
    End date: 2011-11-27

Valacyclovir Hydrochloride
    Administration route: Oral
    Start date: 2011-10-13
    End date: 2011-12-07

Vincristine
    Dosage: 2 mg per course
    Start date: 2011-11-10

Cerubidine
    Dosage: 60 mg per course
    Start date: 2011-11-10

Vfend
    Start date: 2011-11-28
    End date: 2011-12-05

Dexamethasone
    Dosage: daily
    Administration route: Oral
    Start date: 2011-10-20
    End date: 2011-11-27

Phenoxymethyl Penicillin
    Dosage: 3 000 000 iu
    Administration route: Oral
    Start date: 2011-11-18
    End date: 2011-12-07

Kidrolase
    Start date: 2011-10-27

Kidrolase
    Start date: 2011-11-16

Cerubidine
    Dosage: 60 mg per course
    Start date: 2011-11-03

Nexium
    Dosage: daily
    Administration route: Oral
    Start date: 2011-10-17
    End date: 2011-11-11

Vincristine
    Dosage: 2 mg per course
    Start date: 2011-11-03

Kidrolase
    Start date: 2011-11-10

Kidrolase
    Start date: 2011-11-13

Kidrolase
    Start date: 2011-11-06

Nexium
    Administration route: Oral
    Start date: 2011-11-15
    End date: 2011-12-07

Vfend
    Start date: 2011-12-06
    End date: 2011-12-07

Vincristine
    Dosage: 2 mg per course
    Start date: 2011-10-20

Kidrolase
    Start date: 2011-10-30

Kidrolase
    Start date: 2011-11-03

Cerubidine
    Dosage: 60 mg per course
    Start date: 2011-10-27



Possible Vincristine side effects in 30 year old male

Reported by a physician from Israel on 2012-05-21

Patient: 30 year old male

Reactions: Pulmonary Toxicity, Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prednisone
    Dosage: 280 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Bleomycin
    Dosage: 10 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Cytoxan
    Dosage: 650 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 700 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 45 year old female

Reported by a physician from Israel on 2012-05-21

Patient: 45 year old female

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Etoposide
    Dosage: 300 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Cytoxan
    Dosage: 650 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Bleomycin
    Dosage: 10 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Prednisone
    Dosage: 280 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 700 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 46 year old female

Reported by a physician from Israel on 2012-05-18

Patient: 46 year old female

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: 25 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Bleomycin Sulfate
    Dosage: 10 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 700 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Prednisone
    Dosage: 280 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 35 year old male

Reported by a physician from Israel on 2012-05-18

Patient: 35 year old male

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Etoposide
    Dosage: 600 mg/m2600 mg/m2 for 4 cycles of escalated beacopp

Vincristine
    Dosage: 1.4 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2for 2 cycles of standard beacopp
    Indication: Hodgkin's Disease

Bleomycin Sulfate
    Dosage: 10 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Prednisone
    Dosage: 280 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 35 mg/m2 for 4 cycles of escalated beacopp

Etoposide
    Dosage: 300 mg/m2 for 2 cycles of standard beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 1250 mg/m2 for 4 cycles of escalated beacopp

Procarbazine Hydrochloride
    Dosage: 700 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2for 2 cycles of standard beacopp
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 27 year old male

Reported by a physician from Israel on 2012-05-18

Patient: 27 year old male

Reactions: Dyspnoea

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: 35 mg/m2 for 2 cycles of escalated beacopp

Bleomycin Sulfate
    Dosage: 10 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 600 mg/m2 for 2 cycles of escalated beacopp

Doxorubicin HCL
    Dosage: 25 mg/m2 for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease

Prednisone
    Dosage: 280 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2 for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 1250 mg/m2 for 2 cycles of escalated beacopp

Procarbazine Hydrochloride
    Dosage: 700 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2 for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 27 year old male

Reported by a health professional (non-physician/pharmacist) from Israel on 2012-05-08

Patient: 27 year old male

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Vincristine
    Dosage: 1.4 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2 for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2 for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 35 mg/m2 for 2 cycles of escalated beacopp

Bleomycin Sulfate
    Dosage: 10 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 700 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Prednisone TAB
    Dosage: 280 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 1250 mg/m2 for 2 cycles of escalated beacopp

Etoposide
    Dosage: 600 mg/m2 for 2 cycles of escalated beacopp

Cyclophosphamide
    Dosage: 650 mg/m2 for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 27 year old male

Reported by a health professional (non-physician/pharmacist) from Israel on 2012-05-08

Patient: 27 year old male

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Etoposide
    Dosage: 300 mg/m2 for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 600 mg/m2 for 2 cycles of escalated beacopp

Cyclophosphamide
    Dosage: 650 mg/m2 for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 1250 mg/m2 for 2 cycles of escalated beacopp

Procarbazine Hydrochloride
    Dosage: 700 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Bleomycin Sulfate
    Dosage: 10 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2 for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 35 mg/m2 for 2 cycles of escalated beacopp

Prednisone TAB
    Dosage: 280 mg/m2 for all 6 cycles of beacopp
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 46 year old female

Reported by a health professional (non-physician/pharmacist) from Israel on 2012-05-07

Patient: 46 year old female

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prednisone
    Dosage: 280 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Bleomycin Sulfate
    Dosage: 10 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 700 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2 for 6 cycles
    Indication: Hodgkin's Disease



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014